These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8931926)

  • 1. Use of the chemical structure of peptides as the starting point to design nonpeptide agonists and antagonists at peptide receptors: examples with cholecystokinin and tachykinins.
    Horwell DC
    Bioorg Med Chem; 1996 Oct; 4(10):1573-6. PubMed ID: 8931926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.
    Horwell D; Pritchard M; Raphy J; Ratcliffe G
    Immunopharmacology; 1996 Jun; 33(1-3):68-72. PubMed ID: 8856117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of CCKRs and SAR studies of peptidic analog ligands.
    Noble F
    Curr Top Med Chem; 2007; 7(12):1173-9. PubMed ID: 17584139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.
    Mazzone SB; Geraghty DP
    Br J Pharmacol; 2000 Mar; 129(6):1121-31. PubMed ID: 10725260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
    Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cardiac activity by tachykinins in the rat substantia nigra.
    Lessard A; Couture R
    Br J Pharmacol; 2001 Dec; 134(8):1749-59. PubMed ID: 11739252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
    Patacchini R; Barthó L; Maggi CA
    Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antagonists of the tachykinin receptors].
    Kasheverov IE; Utkin IuN; Tsetlin VI
    Bioorg Khim; 1997 Jun; 23(6):451-68. PubMed ID: 9265469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
    Low CM; Black JW; Broughton HB; Buck IM; Davies JM; Dunstone DJ; Hull RA; Kalindjian SB; McDonald IM; Pether MJ; Shankley NP; Steel KI
    J Med Chem; 2000 Sep; 43(19):3505-17. PubMed ID: 11000005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tachykinins and tachykinin receptors in human uterus.
    Patak E; Candenas ML; Pennefather JN; Ziccone S; Lilley A; Martín JD; Flores C; Mantecón AG; Story ME; Pinto FM
    Br J Pharmacol; 2003 Jun; 139(3):523-32. PubMed ID: 12788812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides.
    Horwell DC
    Trends Biotechnol; 1995 Apr; 13(4):132-4. PubMed ID: 7766108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).
    de Tullio P; Delarge J; Pirotte B
    Curr Med Chem; 1999 Jun; 6(6):433-55. PubMed ID: 10213792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for design of non peptide CCK1R agonist/antagonist ligands.
    García-López MT; González-Muñiz R; Martín-Martínez M; Herranz R
    Curr Top Med Chem; 2007; 7(12):1180-94. PubMed ID: 17584140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative structure-activity relationship studies on cholecystokinin antagonists.
    Gupta SP
    Curr Pharm Des; 2002; 8(2):111-24. PubMed ID: 11812253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potencies of agonists acting at tachykinin receptors in the oestrogen-primed rat uterus: effects of peptidase inhibitors.
    Fisher L; Pennefather JN
    Eur J Pharmacol; 1997 Sep; 335(2-3):221-6. PubMed ID: 9369377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzotriazonine as a new core structure for the design of CCK-receptor antagonists.
    Escherich A; Escrieut C; Fourmy D; Moroder L
    J Pept Sci; 1999 Mar; 5(3):155-8. PubMed ID: 10323559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation.
    Kopin AS; McBride EW; Chen C; Freidinger RM; Chen D; Zhao CM; Beinborn M
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5525-30. PubMed ID: 12697901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tachykinin receptors: a radioligand binding perspective.
    Mussap CJ; Geraghty DP; Burcher E
    J Neurochem; 1993 Jun; 60(6):1987-2009. PubMed ID: 8388031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.